# Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

> **NCT00329147** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 20 (estimated)

## Conditions studied

- Depression

## Interventions

- **DRUG:** desvenlafaxine SR
- **DRUG:** desipramine
- **DRUG:** paroxetine

## Key facts

- **NCT ID:** NCT00329147
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329147, "Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00329147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*